Boston Scientific (NYSE:BSX) was upgraded by equities research analysts at BTIG Research from a “neutral” rating to a “buy” rating in a report released on Thursday, MarketBeat Ratings reports. The firm presently has a $31.00 price target on the medical equipment provider’s stock. BTIG Research’s price objective would suggest a potential upside of 17.96% from the company’s current price.

BSX has been the topic of several other research reports. SunTrust Banks set a $34.00 price target on shares of Boston Scientific and gave the company a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, October 30th. BidaskClub downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Oppenheimer reaffirmed a “hold” rating on shares of Boston Scientific in a report on Wednesday, August 9th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.67.

Boston Scientific (BSX) traded up $0.33 on Thursday, hitting $26.28. 18,718,173 shares of the company were exchanged, compared to its average volume of 6,811,406. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $36,238.64, a P/E ratio of 21.63, a price-to-earnings-growth ratio of 2.04 and a beta of 1.00. Boston Scientific has a one year low of $19.67 and a one year high of $29.93.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the firm earned $0.27 earnings per share. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. research analysts predict that Boston Scientific will post 1.25 EPS for the current fiscal year.

In other news, EVP Timothy A. Pratt sold 10,104 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $27.46, for a total value of $277,455.84. Following the transaction, the executive vice president now owns 185,742 shares of the company’s stock, valued at $5,100,475.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy A. Pratt sold 11,061 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the transaction, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders sold 424,802 shares of company stock worth $12,290,609 in the last three months. Insiders own 0.74% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Valeo Financial Advisors LLC bought a new stake in Boston Scientific in the third quarter worth $138,000. Steward Partners Investment Advisory LLC bought a new stake in Boston Scientific in the third quarter worth $139,000. Acrospire Investment Management LLC increased its position in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Boston Scientific by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after purchasing an additional 720 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in Boston Scientific in the second quarter worth $191,000. Institutional investors own 90.55% of the company’s stock.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/30/btig-research-upgrades-boston-scientific-bsx-to-buy.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.